Category Archives: News

Clarity signs supply agreement for Ac-225 with TerraPower Isotopes and launches Ac-225 bisPSMA program

Sydney, Australia 16 July 2024 Highlights Agreement signed with TerraPower Isotopes (TerraPower) for the supply of the therapeutic alpha-emitting isotope, actinium-225 (Ac-225 or 225Ac), for Clarity’s first Targeted Alpha-particle Therapy (TAT) program with bisPSMA. Clarity is now well positioned to develop a best-in-class TAT 225Ac-bisPSMA product with secure supply combined with the increased uptake and…

Clarity Receives $10 million R&D Tax Incentive Refund

Sydney, Australia 24 June 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that it has received a $9,951,692 Research and Development (R&D) Tax Incentive refund as part of the…

Clarity confirms no supply disruptions for its ongoing clinical trial programs

Sydney, Australia 7 June 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, confirms Clarity’s Targeted Copper Theranostic (TCT) products and clinical development programs using copper-67 (Cu-67 or 67Cu) are unaffected by a recent…

Clarity strengthens Cu-64 network with new supply agreement with SpectronRx

Sydney, Australia 30 May 2024 Highlights Agreement with SpectronRx ensures seamless supply of the diagnostic copper-64 (Cu-64 or 64Cu) isotope for Clarity’s products which continue to progress through clinical trials, including a pivotal Phase III clinical trial. Cu-64 has an ideal 12.7-hour half-life that helps to overcome the overwhelming supply restraints of current-generation radiodiagnostics based…

Clarity to present at three world leading conferences

Sydney, Australia 3 May 2024 Highlights Eight abstracts have been accepted by the American Urological Association (AUA), American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meetings, showcasing the latest data from Clarity’s oncology portfolio. Abstracts of Clarity’s diagnostic clinical trials COBRA and CLARIFY were accepted for…

Clarity Update: Complete response in first patient ever treated with 2 doses of Cu-67 SAR-bisPSMA at 8GBq

Sydney, Australia 30 April 2024 Highlights A complete response, based on Response Evaluation Criteria In Solid Tumours (RECIST v1.1) assessment, has been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level. The patient remains with undetectable levels of Prostate Specific…

Clarity successfully completes fully underwritten Retail Entitlement Offer

Sydney, Australia 24 April 2024 Highlights Clarity has successfully completed the fully underwritten Retail Entitlement Offer component of its capital raising, raising approximately $10.8 million (before costs) Completion of the Retail Entitlement Offer represents the final stage of the fully underwritten Placement and Entitlement Offer announced by Clarity on 26 March 2024 which has raised…

Clarity enters into Cu-67 SAR-bisPSMA Clinical Supply Agreement with NorthStar supporting late-stage therapy trials

Sydney, Australia 4 April 2024 Highlights New Clinical Supply Agreement with NorthStar for the production of 67Cu-SAR-bisPSMA drug product ensures seamless product supply as Clarity plans for upcoming pivotal therapy trials. Uniquely provides large-scale manufacturing of both the therapeutic isotope (copper-67) and cGMP radiopharmaceutical product in the United States ready for shipment to clinical sites.…

Despatch of Retail Entitlement Offer Booklet

Sydney, Australia 4 April 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”) announced on Tuesday, 26 March 2024, a fully underwritten pro rata accelerated non-renounceable entitlement offer (“Entitlement Offer”) to eligible shareholders to subscribe for one (1) new fully paid ordinary Clarity share (“New Share”) for every thirty three (33) existing fully paid ordinary Clarity…

Clarity successfully completes Placement and Institutional Entitlement Offer

Sydney, Australia 28 March 2024 Highlights Clarity has successfully completed the Placement and Institutional Entitlement Offer component of its capital raising, raising $110 million in total The Placement and Institutional Entitlement Offer received strong support from a broad range of new and existing institutional investors The strengthened balance sheet provides Clarity with funding to continue…